Skip to main content

Advertisement

SpringerLink
Log in

Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

It remains unclear whether fatty liver is a risk factor for the onset of abnormal glucose tolerance in any patient. The objective of this study was to clarify the relationship between fatty liver and the onset of impaired fasting glucose according to baseline fasting plasma glucose (FPG) levels.

Methods

This community-based longitudinal cohort study included 7,905 adults (3,863 men, 4,042 women; age range, 18–80 years) who had at least two annual checkups between 2003 and 2013. Those with FPG levels ≥110 mg/dl, taking anti-diabetic agents, and/or testing positive for hepatitis B surface antigen or anti-hepatitis C virus antibody were excluded, leaving 7,203 participants eligible for inclusion. All participants were divided into quartiles derived from their FPG levels at baseline. FPG ≥110 mg/dl during the observation period was defined as onset of IFG.

Results

Onset of IFG was found in 7.7 % of men and 2.1 % of women (p < 0.001). After adjusting for age, body mass index, systolic blood pressure, triacylglycerol, high-density lipoprotein cholesterol, uric acid, creatinine, family history of diabetes, alcohol consumption, and current smoking, a positive association was found between fatty liver and the onset of IFG in both sexes with the highest quartile of FPG levels [men: adjusted hazard ratio (aHR) 1.823, 95 % confidence interval (CI) 1.316–2.534, p < 0.001; women: aHR 2.016, 95 % CI 1.117–3.6, p = 0.02].

Conclusions

Our results suggest that fatty liver is independently associated with an increased risk of developing IFG in individuals with high FPG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol. 2011;8:228–36.

    Article  PubMed  Google Scholar 

  2. Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep. 2013;62:1–96.

    PubMed  Google Scholar 

  3. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889–95.

    Article  CAS  PubMed  Google Scholar 

  4. Fraser A, Harris R, Sattar N, et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hanley AJ, Williams K, Festa A, Insulin Resistance Atherosclerosis Study, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2004;53:2623–32.

    Article  CAS  PubMed  Google Scholar 

  6. Wannamethee SG, Shaper AG, Lennon L, et al. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28:2913–8.

    Article  CAS  PubMed  Google Scholar 

  7. Ford ES, Schulze MB, Bergmann MM, et al. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care. 2008;31:1138–43.

    Article  PubMed  Google Scholar 

  8. Monami M, Bardini G, Lamanna C, et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. 2008;57:387–92.

    Article  CAS  PubMed  Google Scholar 

  9. Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010;25:352–6.

    Article  CAS  PubMed  Google Scholar 

  10. Kim CH, Park JY, Lee KU, et al. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet Med. 2008;25:476–81.

    Article  CAS  PubMed  Google Scholar 

  11. Sung KC, Jeong WS, Wild SH, et al. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care. 2012;35:717–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kato M, Noda M, Suga H, et al. Fasting plasma glucose and incidence of diabetes—implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA cohort study. J Atheroscler Thromb. 2009;16:857–61.

    Article  CAS  PubMed  Google Scholar 

  13. Moriuchi T, Oka R, Yagi K, et al. Diabetes progression from “high-normal” glucose in school teachers. Intern Med. 2010;49:1271–6.

    Article  CAS  PubMed  Google Scholar 

  14. Miyake T, Kumagi T, Furukawa S, et al. Hyperuricemia is a risk factor for the onset of impaired fasting glucose in men with a high plasma glucose level: a community-based study. PLoS One. 2014;9:e107882.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.

    Article  PubMed  Google Scholar 

  16. Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954–61.

    Article  PubMed  Google Scholar 

  17. Miyake T, Kumagi T, Hirooka M, et al. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696–703.

    Article  CAS  PubMed  Google Scholar 

  18. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization; 2006.

    Google Scholar 

  19. Kuzuya T, Nakagawa S, Satoh J, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65–85.

    Article  PubMed  Google Scholar 

  20. American Diabetes Association. Screening for diabetes. Diabetes Care. 2002;25:s21–4.

    Article  Google Scholar 

  21. Harita N, Hayashi T, Sato KK, et al. Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care. 2009;32:424–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sairenchi T, Iso H, Nishimura A, et al. Cigarette smoking and risk of type 2 diabetes mellitus among middle-aged and elderly Japanese men and women. Am J Epidemiol. 2004;160:158–62.

    Article  PubMed  Google Scholar 

  23. Waki K, Noda M, Sasaki S, JPHC Study Group, et al. Alcohol consumption and other risk factors for self-reported diabetes among middle-aged Japanese: a population-based prospective study in the JPHC study cohort I. Diabet Med. 2005;22:323–31.

    Article  CAS  PubMed  Google Scholar 

  24. Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30:2940–4.

    Article  CAS  PubMed  Google Scholar 

  25. Yamazaki H, Tsuboya T, Tsuji K, et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care. 2015;38:1673–9.

    Article  CAS  PubMed  Google Scholar 

  26. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22:1141–5.

    Article  CAS  PubMed  Google Scholar 

  27. Su CC, Wang K, Hsia TL, et al. Association of nonalcoholic fatty liver disease with abnormal aminotransferase and postprandial hyperglycemia. J Clin Gastroenterol. 2006;40:551–4.

    Article  CAS  PubMed  Google Scholar 

  28. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.

    Article  CAS  PubMed  Google Scholar 

  29. Choi HY, Hwang SY, Lee CH, et al. Increased selenoprotein p levels in subjects with visceral obesity and nonalcoholic fatty liver disease. Diabetes Metab J. 2013;37:63–71.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Stefan N, Hennige AM, Staiger H, et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006;29:853–7.

    Article  CAS  PubMed  Google Scholar 

  31. Haasemann M, Nawratil P, Müller-Esterl W. Rat tyrosine kinase inhibitor shows sequence similarity to human alpha 2-HS glycoprotein and bovine fetuin. Biochem J. 1991;274:899–902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Misu H, Takamura T, Takayama H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 2010;12:483–95.

    Article  CAS  PubMed  Google Scholar 

  33. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345–53.

    Article  CAS  PubMed  Google Scholar 

  34. Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1093–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (JSPS KAKENHI 15K00874 to T.M., 15K09006 to Y.H.), and a research grant from Ehime University.

Author information

Authors and Affiliations

  1. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan

    Teruki Miyake, Masashi Hirooka, Osamu Yoshida, Teru Kumagi, Mitsuhito Koizumi, Shin Yamamoto, Taira Kuroda, Eiji Arimitsu, Eiji Takeshita, Masanori Abe, Bunzo Matsuura & Yoichi Hiasa

  2. Department of Public Health, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan

    Shinya Furukawa

  3. Department of Community Medicine, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, Japan

    Teru Kumagi

  4. Ehime General Health Care Association, Misake, Matsuyama, Ehime, Japan

    Mitsuhito Koizumi & Kohichiro Kitai

Authors
  1. Teruki Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Hirooka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Osamu Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinya Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Teru Kumagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mitsuhito Koizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shin Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Taira Kuroda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eiji Arimitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eiji Takeshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masanori Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kohichiro Kitai
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Bunzo Matsuura
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yoichi Hiasa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoichi Hiasa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Tables (DOCX 26 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyake, T., Hirooka, M., Yoshida, O. et al. Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels. J Gastroenterol 52, 237–244 (2017). https://doi.org/10.1007/s00535-016-1234-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-016-1234-9

Keywords

Search

Navigation